Discover great EU-funded Innovations
INNOVATOR
ACHILLES THERAPEUTICS UK LIMITED
SHARE:
DETAILS
Organisation type
Small or Medium Enterprise
Address
245 HAMMERSMITH ROAD
W6 8PW LONDON
United Kingdom
Contact
E-mail this innovator
Funding
Total H2020 EU funding 817k
Achilles Therapeutics is a biopharmaceutical company developing precision T cell therapies that target clonal neoantigens. Neoantigens are protein markers unique to each individual that are present on the surface of a cancer cell and can be detected by the immune system. Our approach is based on the science of tumor evolution which allows us to leverage our bioinformatics platform - powered by artificial intelligence (AI) - to identify ‘clonal’ neoantigens that arise early in cancer development and are retained as each tumor continues to grow and mutate. By directing T cell therapies against clonal neoantigens, which are present on all cancer cells and are completely absent from normal cells, we can for the first time target every cancer cell without attacking healthy tissue.
This innovator is on:
Economic sectors this organisation is active in:
  • HUMAN HEALTH AND SOCIAL WORK ACTIVITIES > Human health activities
  • PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES > Scientific research and development
  • MANUFACTURING > Other manufacturing
Partnership
This organisation is seeking partnerships of the following nature:
  • Investment
  • Strategic Business Partners
  • Licensing opportunities
 
Innovations
This organisation has been identified as a Key Innovator for the following 2 EU-funded innovations:
All innovations listed above are ranked by freshness of data, i.e. the innovations most recently analysed by Innovation Radar appear at the top